Experimental Alzheimer’s drug delivers promising Phase 2 trial results
According to the new data from pharmaceutical company Eli Lilly, the antibody donanemab slowed cognitive decline by 32% compared to a placebo.
Experimental Alzheimer’s drug delivers promising Phase 2 trial results Read more